Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc Stock Forecast & Price Prediction

Live Apellis Pharmaceuticals Inc Stock (APLS) Price
$29.98

3

Ratings

  • Buy 3
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$29.98

P/E Ratio

-6.74

Volume Traded Today

$4.8M

Dividend

Dividends not available for APLS

52 Week High/low

73.80/24.34

Apellis Pharmaceuticals Inc Market Cap

$3.73B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $APLS ๐Ÿ›‘

Before you buy APLS you'll want to see this list of ten stocks that have huge potential. Want to see if APLS made the cut? Enter your email below

APLS Summary

Based on ratings from 3 stock analysts, the Apellis Pharmaceuticals Inc stock price is expected to increase by 54.17% in 12 months. This is calculated by using the average 12-month stock price forecast for Apellis Pharmaceuticals Inc. The lowest target is $24 and the highest is $78. Please note analyst price targets are not guaranteed and could be missed completely.

APLS Analyst Ratings

APLS is a stock in Healthcare which has been forecasted to be worth $46.22 as an average. On the higher end, the forecast price is $78 USD by Justin Kim from Oppenheimer and on the lower end APLS is forecasted to be $24 by Luca Issi from RBC Capital.

APLS stock forecast by analyst

These are the latest 20 analyst ratings of APLS.

Analyst/Firm

Rating

Price Target

Change

Date

Colleen Kusy
Baird

Outperform

$55

Maintains

Nov 7, 2024
Yigal Nochomovitz
Citigroup

Buy

$51

Maintains

Nov 6, 2024
Greg Harrison
Scotiabank

Sector Perform

$30

Maintains

Nov 6, 2024
Salveen Richter
Goldman Sachs

Buy

$36

Maintains

Nov 6, 2024
Douglas Tsao
HC Wainwright & Co.

Buy

$57

Maintains

Nov 6, 2024
Luca Issi
RBC Capital

Sector Perform

$24

Maintains

Nov 6, 2024
Biren Amin
Piper Sandler

Neutral

$32

Maintains

Nov 6, 2024
Joseph Stringer
Needham

Buy

$60

Maintains

Nov 6, 2024
Tazeen Ahmad
B of A Securities

Buy

$47

Maintains

Nov 6, 2024
Justin Kim
Oppenheimer

Outperform

$40

Maintains

Nov 6, 2024
Derek Archila
Wells Fargo

Equal-Weight

$30

Maintains

Nov 6, 2024
Luca Issi
RBC Capital

Sector Perform

$25

Reiterates

Nov 4, 2024
Graig Suvannavejh
Mizuho

Neutral

$38

Maintains

Oct 24, 2024
Greg Harrison
Scotiabank

Sector Perform

$35

Initiates

Oct 16, 2024
Lachlan Brown
William Blair

Outperform


Initiates

Oct 16, 2024
Derek Archila
Wells Fargo

Equal-Weight

$43

Maintains

Sep 24, 2024
Colleen Kusy
Baird

Outperform

$92

Maintains

Sep 23, 2024
Joseph Stringer
Needham

Buy

$85

Reiterates

Sep 20, 2024
Graig Suvannavejh
Mizuho

Neutral

$39

Maintains

Sep 20, 2024
Anupam Rama
JP Morgan

Overweight

$57

Maintains

Sep 13, 2024

APLS Company Information

What They Do: Develops therapies targeting the complement system.

Business Model: The company generates revenue by commercializing its therapeutic compounds, primarily EMPAVELI and SYFOVRE, which treat various autoimmune and inflammatory diseases. Additionally, it engages in collaborations and licensing agreements to enhance its product pipeline and expand market reach.

Other Information: Apellis Pharmaceuticals is focused on innovative treatments for conditions linked to the complement system, with ongoing clinical trials for its new drug candidates, including APL-3007. The company has strategic partnerships to leverage advanced technologies for drug discovery, positioning itself as a leader in complement-driven disease therapies.
APLS
Apellis Pharmaceuticals Inc (APLS)

When did it IPO

2017

Staff Count

702

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Cedric Francois M.D., Ph.D.

Market Cap

$3.73B

Apellis Pharmaceuticals Inc (APLS) Financial Data

In 2023, APLS generated $396.6M in revenue, which was a increase of 425.83% from the previous year. This can be seen as a signal that APLS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$250.6M

Revenue From 2021

$66.6M

-73.44 %
From Previous Year

Revenue From 2022

$75.4M

13.31 %
From Previous Year

Revenue From 2023

$396.6M

425.83 %
From Previous Year
  • Revenue TTM $715.2M
  • Operating Margin TTM -24.0%
  • Gross profit TTM $338.1M
  • Return on assets TTM -16.2%
  • Return on equity TTM -106.6%
  • Profit Margin -35.0%
  • Book Value Per Share 1.94%
  • Market capitalisation $3.73B
  • Revenue for 2021 $66.6M
  • Revenue for 2022 $75.4M
  • Revenue for 2023 $396.6M
  • EPS this year (TTM) $-2.12

Apellis Pharmaceuticals Inc (APLS) Latest News

News Image

Tue, 05 Nov 2024

Sentiment - NEUTRAL

Source - The Motley Fool

Summary - Sales of the company's leading commercial product fell short of expectations.

Why It Matters - Underperformance in sales can signal weak demand or competitive pressures, potentially leading to lower revenue projections and impacting stock valuation negatively.

News Image

Tue, 05 Nov 2024

Sentiment - NEGATIVE

Source - Investors Business Daily

Summary - Apellis Pharmaceuticals' stock fell after third-quarter sales for its eye drug, Syfovre, significantly missed Wall Street expectations.

Why It Matters - Apellis stock drop signals potential revenue issues and concerns about product demand, impacting investor confidence and future growth projections.

News Image

Tue, 05 Nov 2024

Sentiment - NEUTRAL

Source - Seeking Alpha

Summary - Apellis Pharmaceuticals will hold its Q3 2024 earnings conference call on November 5, 2024, at 8:30 AM ET, featuring key executives and various financial analysts.

Why It Matters - The Q3 earnings call for Apellis Pharmaceuticals is a key event for assessing financial performance, strategic direction, and market outlook, influencing stock valuations and investment decisions.

News Image

Tue, 05 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Apellis Pharmaceuticals (Nasdaq: APLS) reported its Q3 2024 financial results and business highlights on November 5, 2024.

Why It Matters - Apellis Pharmaceuticals' Q3 2024 financial results can indicate its growth, profitability, and market position, influencing stock performance and investor sentiment.

News Image

Tue, 05 Nov 2024

Sentiment - NEGATIVE

Source - Zacks Investment Research

Summary - Apellis Pharmaceuticals (APLS) reported a quarterly loss of $0.46 per share, missing the estimate of $0.32. This is an improvement from a loss of $1.17 per share a year earlier.

Why It Matters - Apellis's larger-than-expected quarterly loss may signal ongoing financial challenges, potentially affecting stock performance and investor sentiment amid recovery from last year's higher losses.

News Image

Tue, 05 Nov 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Apellis Pharmaceuticals (APLS) reported revenue and EPS for Q3 2024. Investors should compare these figures with Wall Street estimates and year-ago performance.

Why It Matters - Comparing Apellis Pharmaceuticals' revenue and EPS to Wall Street estimates and previous year data provides insight into growth potential and market expectations, influencing stock valuation.

...

APLS Frequently asked questions

The highest forecasted price for APLS is $78 from Justin Kim at Oppenheimer.

The lowest forecasted price for APLS is $24 from Luca Issi from RBC Capital

The APLS analyst ratings consensus are 3 buy ratings, 0 hold ratings, and 0 sell ratings.